Hers shipped compounded semaglutide and Hims hit a $1.7B annualized run-rate. Then FDA pulled the shortage list. Welcome to the most regulated lane in healthtech.
GLP-1 telehealth is the most capital-intensive, most regulated, and most fragile lane in 2026 consumer healthtech. Hims & Hers added Wegovy and compounded semaglutide to their offering in mid-2024 and their weight-loss vertical hit a $1.7B annualized run-rate within a year. Ro followed. Henry, Mochi, Eden Health, WeightWatchers Clinic, and a long tail of indie shops piled in. Then the rules changed: FDA removed semaglutide from its drug shortage list in October 2024, and tirzepatide in early 2025, which meant 503A and 503B compounding pharmacies were no longer legally permitted to mass-produce copies of Wegovy and Zepbound. A series of court fights, administrative orders, and selective enforcement actions followed through 2025, with FDA's 2026 enforcement crackdown — which OPC ATLAS has been tracking closely — now actively closing the compounded-GLP-1 loophole. Branded Wegovy and Zepbound remain available but at $1,000+/month list price, which collapses unit economics that were calibrated to $200-$400 compounded. The honest read: solo builders cannot enter this track. Capital required is $10M+ to ship anything credible. The regulatory tripwires are everywhere — DEA controlled substance flags on overlapping GLP-1+stimulant combos, state telehealth corporate-practice-of-medicine doctrines, state pharmacy board enforcement on compounding, FTC scrutiny on weight-loss claims. The only paths that work in 2026 are (a) capital-backed players who can pivot to branded-only economics and find adjacent revenue (MNT, CGM, behavioral coaching), (b) tooling/EHR/clinician-network infrastructure plays selling to the operators rather than the patients, or (c) sit this one out and re-examine in 2027 once the regulatory dust settles.
Hers added compounded semaglutide and Wegovy in mid-2024, scaling fast off existing brand and CAC machine. Received an FDA warning letter on its February 2025 Super Bowl ad. Pivoted in 2025 to branded-plus-personalization framing. The category bellwether — when Hims pivots, the rest follow within a quarter.
Multi-condition telehealth platform. Added GLP-1 in 2023. More diversified than Hims, with vertical playbooks across cardiometabolic, men's health, fertility. The "platform with GLP-1 as one SKU" model that survives regulatory shocks better than a single-condition shop.
The boot-strapped poster child of the compounded-GLP-1 wave. Grew very fast with TikTok-led marketing, no outside capital. Now under sustained pressure from the shortage-list reversal. A test case for whether profitable bootstrap survives a regulatory tightening.
Founded by Myra Ahmad MD, a board-certified obesity medicine physician. Positioned as the "clinically rigorous" GLP-1 telehealth shop with full lipid panels, labs, and full obesity medicine protocols. The closest to a defensible long-term position — clinical depth that compounding-only competitors can't match.
Started with hormone optimization, expanded into GLP-1. Premium positioning, integrated lab work, focus on outcomes data. One of the smaller players that may survive precisely because the brand isn't bet on compounded-pricing economics.
WeightWatchers acquired Sequence in 2023 and rebranded it as WW Clinic. Bundles behavioral coaching with GLP-1 prescriptions. WeightWatchers parent company filed Chapter 11 in May 2025, emerged from bankruptcy later that year — cautionary lesson about how a 60-year-old brand still got cratered by GLP-1 dynamics it tried to surf.
Noom's GLP-1 arm, launched in 2023 to recover the behavioral-weight-loss revenue lost to the GLP-1 wave. A defensive play more than an offensive one. Shows that even with a 2,000-person team and decades of behavioral data, you can't sit out the drug — you have to add it.
The upstream player. Lilly launched LillyDirect in January 2024 — direct shipment of branded Zepbound (and Mounjaro) to verified patients, bypassing pharmacy retail. This is the existential threat to telehealth middlemen: when the pharma company runs the D2C funnel, what's the telehealth layer for? Lilly is signaling it will absorb the margin.
Anything below this number and you cannot ship a real product. Regulatory affairs, multi-state clinician credentialing, pharmacy partnership, insurance billing infrastructure, ad creative review pipeline — each one of these is its own six-figure cost center.
EHR for obesity medicine clinicians, pharmacy network management, clinician-credentialing workflow, MNT-integration software, eligibility-and-PA tooling — the picks-and-shovels lane is fundable, smaller capital requirement, less regulatory exposure. Berry Street's playbook applied to GLP-1.
Board-certified obesity medicine (ABOM) physicians are the credibility currency in this category. Mochi has Myra Ahmad MD; survivors all have a senior clinician at the helm. Without one you cannot land payer contracts, defend ad copy, or recruit a credible clinician network at scale.
FDA removed semaglutide and tirzepatide from the shortage list in 2024-2025. Compounding for these molecules under the shortage exception is no longer legal. Some players are leaning on the "personalization" carve-out — but FDA's 2026 enforcement crackdown is closing this loophole. If your spreadsheet assumes $200-$400 compounded GLP-1 wholesale, your business is operating on borrowed time.
Multi-state telehealth licensing alone burns 12-18 months for a small ops team. Add pharmacy partnerships, BAA-compliant infrastructure, ad-creative legal review, clinician credentialing, and HIPAA. You need an ops team of 10+ before you ship one patient.
It was, briefly, in 2023-2024. In 2026 it's a regulatory and clinical-outcomes game. FTC sent enforcement letters on misleading weight-loss claims through 2024-2025. State pharmacy boards are filing actions. The era of "Super Bowl ads + TikTok creators + compounded supply" is finished.
Repeat founders, ex-Hims/Ro operators, $10M+ pre-seed minimum
Healthtech engineers with payer or pharmacy ops experience
Anyone not in the first two categories
Ex-Hims, ex-Ro, ex-Henry, ex-WW Clinic operators with multi-state telehealth ops experience. The capital partners, the lawyers, the obesity medicine MDs, the pharmacy relationships — these are not Googleable. They are 5-10 years of relationship-building you've already done.
Board-certified obesity medicine (ABOM) physicians. The credibility currency of this entire category. Paired with a strong operator co-founder, this is one of the few times a clinician-founder beats a serial-startup founder on this kind of track.
Relationships at self-insured employers, PBMs, ASOs, large health plans. Employer-funded GLP-1 access is the next big addressable market, but it's a slow door-to-door sale. Slower than D2C, but harder to displace.
5 min · 12 questions · Free · Get your archetype + top 3 matching tracks
Take the quiz →